{"id":3319,"date":"2024-07-15T10:00:26","date_gmt":"2024-07-15T08:00:26","guid":{"rendered":"https:\/\/www.fondazionebonadonna.eu\/?p=3319"},"modified":"2024-07-10T10:41:32","modified_gmt":"2024-07-10T08:41:32","slug":"oral-serd-camizestrant-in-er-her2-advanced-breast-cancer","status":"publish","type":"post","link":"https:\/\/www.fondazionebonadonna.eu\/en\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\/","title":{"rendered":"Oral SERD camizestrant in ER+, HER2- advanced breast cancer"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_custom_heading text=&#8221;A phase I trial supports a tolerable safety profile and suggests clinical efficacy in heavily pretreated patients&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]Results of the phase I SERENA-1 trial, <a href=\"https:\/\/www.annalsofoncology.org\/article\/S0923-7534(24)00138-8\/fulltext\" target=\"_blank\" rel=\"noopener\">recently published on Annals of Oncology<\/a>, showed safety and tolerability of camizestrant, a next-generation oral selective ER antagonist and degrader (SERD) and pure ER antagonist, in ER+, HER2- advanced breast cancer patients, suggesting clinical benefits in a\u00a0 heavily pretreated population.<\/p>\n<p>SERENA-1 trial is a phase I, multi-part, open-label study which enrolled 108 pre- and post-menopausal women with ER+, HER2\u2212 advanced breast cancer to determine the safety and tolerability of camizestrant monotherapy and define doses for clinical evaluation. 86.1% of patients experienced treatment-related adverse event, 82.4% of which were grade 1 or 2; estimated half-life is 20-23 h. Efficacy was observed at all doses investigated, including in patients with prior CDK4\/6 inhibitors and\/or fulvestrant treatment, with and without baseline <em>ESR1<\/em> mutations, and with visceral disease, including liver metastases. As authors say, \u00abcamizestrant has a well-tolerated safety profile, pharmacokinetics characteristics suitable for once-daily dosing, and evidence of pharmacodynamic and clinical efficacy in heavily pre-treated patients. The study established that the doses of interest for phase II testing were 75, 150, and 300 mg once daily. The ongoing subsequent parts of SERENA-1 aim to further investigate camizestrant in combination with other anticancer agents relevant to ER+, HER2\u2212 advanced breast cancer, including palbociclib, abemaciclib,\u00a0everolimus, and capivasertib\u00bb.[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/2&#8243;][vc_single_image image=&#8221;2883&#8243; img_size=&#8221;large&#8221;][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_custom_heading text=&#8221;A phase I trial supports a tolerable safety profile and suggests clinical efficacy in heavily pretreated patients&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]Results of the phase I SERENA-1<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":2,"featured_media":2884,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39,21],"tags":[],"class_list":["post-3319","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oral SERD camizestrant in ER+, HER2- advanced breast cancer - Fondazione Gianni Bonadonna<\/title>\n<meta name=\"description\" content=\"Un trial di fase I indica un profilo di sicurezza tollerabile e suggerisce un\u2019efficacia clinica in pazienti molto pretrattate\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fondazionebonadonna.eu\/en\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oral SERD camizestrant in ER+, HER2- advanced breast cancer - Fondazione Gianni Bonadonna\" \/>\n<meta property=\"og:description\" content=\"Un trial di fase I indica un profilo di sicurezza tollerabile e suggerisce un\u2019efficacia clinica in pazienti molto pretrattate\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fondazionebonadonna.eu\/en\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-15T08:00:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2023\/09\/Depositphotos_425875532_XL.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2500\" \/>\n\t<meta property=\"og:image:height\" content=\"1500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fondazione Gianni Bonadonna\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\\\/\"},\"author\":{\"name\":\"Fondazione Gianni Bonadonna\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"headline\":\"Oral SERD camizestrant in ER+, HER2- advanced breast cancer\",\"datePublished\":\"2024-07-15T08:00:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\\\/\"},\"wordCount\":281,\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Depositphotos_425875532_XL.jpg\",\"articleSection\":[\"Events\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\\\/\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\\\/\",\"name\":\"Oral SERD camizestrant in ER+, HER2- advanced breast cancer - Fondazione Gianni Bonadonna\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Depositphotos_425875532_XL.jpg\",\"datePublished\":\"2024-07-15T08:00:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"description\":\"Un trial di fase I indica un profilo di sicurezza tollerabile e suggerisce un\u2019efficacia clinica in pazienti molto pretrattate\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Depositphotos_425875532_XL.jpg\",\"contentUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Depositphotos_425875532_XL.jpg\",\"width\":2500,\"height\":1500},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oral SERD camizestrant in ER+, HER2- advanced breast cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/\",\"name\":\"Fondazione Gianni Bonadonna\",\"description\":\"Fondazione Gianni Bonadonna\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\",\"name\":\"Fondazione Gianni Bonadonna\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"caption\":\"Fondazione Gianni Bonadonna\"},\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/author\\\/fgb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oral SERD camizestrant in ER+, HER2- advanced breast cancer - Fondazione Gianni Bonadonna","description":"Un trial di fase I indica un profilo di sicurezza tollerabile e suggerisce un\u2019efficacia clinica in pazienti molto pretrattate","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fondazionebonadonna.eu\/en\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Oral SERD camizestrant in ER+, HER2- advanced breast cancer - Fondazione Gianni Bonadonna","og_description":"Un trial di fase I indica un profilo di sicurezza tollerabile e suggerisce un\u2019efficacia clinica in pazienti molto pretrattate","og_url":"https:\/\/www.fondazionebonadonna.eu\/en\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\/","og_site_name":"Fondazione Gianni Bonadonna","article_published_time":"2024-07-15T08:00:26+00:00","og_image":[{"width":2500,"height":1500,"url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2023\/09\/Depositphotos_425875532_XL.jpg","type":"image\/jpeg"}],"author":"Fondazione Gianni Bonadonna","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fondazione Gianni Bonadonna","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\/#article","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\/"},"author":{"name":"Fondazione Gianni Bonadonna","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"headline":"Oral SERD camizestrant in ER+, HER2- advanced breast cancer","datePublished":"2024-07-15T08:00:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\/"},"wordCount":281,"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2023\/09\/Depositphotos_425875532_XL.jpg","articleSection":["Events"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\/","url":"https:\/\/www.fondazionebonadonna.eu\/en\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\/","name":"Oral SERD camizestrant in ER+, HER2- advanced breast cancer - Fondazione Gianni Bonadonna","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2023\/09\/Depositphotos_425875532_XL.jpg","datePublished":"2024-07-15T08:00:26+00:00","author":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"description":"Un trial di fase I indica un profilo di sicurezza tollerabile e suggerisce un\u2019efficacia clinica in pazienti molto pretrattate","breadcrumb":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fondazionebonadonna.eu\/en\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\/#primaryimage","url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2023\/09\/Depositphotos_425875532_XL.jpg","contentUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2023\/09\/Depositphotos_425875532_XL.jpg","width":2500,"height":1500},{"@type":"BreadcrumbList","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/oral-serd-camizestrant-in-er-her2-advanced-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fondazionebonadonna.eu\/en\/"},{"@type":"ListItem","position":2,"name":"Oral SERD camizestrant in ER+, HER2- advanced breast cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.fondazionebonadonna.eu\/#website","url":"https:\/\/www.fondazionebonadonna.eu\/","name":"Fondazione Gianni Bonadonna","description":"Fondazione Gianni Bonadonna","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fondazionebonadonna.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146","name":"Fondazione Gianni Bonadonna","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","caption":"Fondazione Gianni Bonadonna"},"url":"https:\/\/www.fondazionebonadonna.eu\/en\/author\/fgb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/3319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/comments?post=3319"}],"version-history":[{"count":0,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/3319\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media\/2884"}],"wp:attachment":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media?parent=3319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/categories?post=3319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/tags?post=3319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}